Back to search

Peptide record

TPDB41432

C7A- Δ C7A-Δ Anticancer standard
23 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41432
C7A- Δ C7A-Δ
Anticancer
Cancer-related peptides
ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb dbACP iACP-DRLF
standard
No
A 23-aa standard natural anticancer peptide sequence curated from ACP740 _ACP240, AntiCP 2.0, CancerPPD 2.0, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
KILRGVAKKIMRTFLRRILTGKK-NH2
Physicochemical Analysis
C124H228N40O26S1
NDCEQHPSWY
K
2727.49
12.89
9
0
10
+9
4.42
-0.178
118.70
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
2
Residue Composition
number
1
A
4
R
0
N
0
D
0
C
0
E
0
Q
2
G
0
H
3
I
3
L
5
K
1
M
1
F
0
P
0
S
2
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 1 R: 4 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 3 L: 3 K: 5 M: 1 F: 1 P: 0 S: 0 T: 2 W: 0 Y: 0 V: 1
Chemical Descriptors
23
C124H228N40O26S1
2727.49
12.89
+9
4.42
-0.178
Amidation
L
Linear
Free
Antimicrobial Anticancer
Synthetic peptide NK-2 variants
Evidence Records 8 records
Evidence 1 Activity

Activity

IC50
IC50 =7.5 ± 0.4 µM
Anticancer
7.5

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
30-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 =13.8 ± 2.0 µM
Anticancer
13.8

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
2-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 3 Activity

Activity

IC50
IC50 =9.3 ± 1.5 µM
Anticancer
9.3

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
4-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 4 Activity

Activity

IC50
IC50 =13.1 ± 0.9 µM
Anticancer
13.1

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 5 Activity

Activity

IC50
IC50= 7.5±0.4 µM
Anticancer
7.5

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
30-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 6 Activity

Activity

IC50
IC50= 13.8±2.0 µM
Anticancer
13.8

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
2-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 7 Activity

Activity

IC50
IC50= 9.3±1.5 µM
Anticancer
9.3

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
4-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 8 Activity

Activity

IC50
IC50= 13.1±0.9 µM
Anticancer
13.1

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013